Generex Biotechnology Corporation announced its wholly owned immunotherapeutic subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totalling $488,958.50, by the US Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

The Antigen Express Therapeutic Discovery Projects are entitled for the treatment of breast cancer and prostate cancer. The Peptide vaccine being developed by Antigen Express is an off-the-shelf product designed to reduce the risk of relapse in cancer patients. It is the subject of a controlled, randomized phase II trial in patients with breast cancer which has yielded positive interim results.

Based on positive results from a phase I trial in prostate cancer patients, preparations for a phase II clinical trial in prostate cancer patients are underway. In all studies, the self-potentiating vaccine has shown very low toxicity and generates a good immune response.

The Therapeutic Discovery Project grants are targeted for projects that show a reasonable potential to: result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions reduce the long-term growth of health care costs in US or significantly advance the goal of curing cancer within 30 years.

Grant allocations also take into consideration which shows the greatest potential to create and sustain high-quality, high-paying US jobs, and to advance US competitiveness in life, biological, and medical sciences.

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. It has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).

Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.